SOPHiA GENETICS (NASDAQ:SOPH) Sees Unusually-High Trading Volume – Here’s What Happened

Shares of SOPHiA GENETICS SA (NASDAQ:SOPH) saw unusually-strong trading volume on Tuesday . 229,338 shares traded hands during mid-day trading, an increase of 31% from the previous session’s volume of 174,682 shares.The stock last traded at $6.2430 and had previously closed at $5.98.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on SOPH. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. BTIG Research restated a “buy” rating and issued a $8.00 price objective on shares of SOPHiA GENETICS in a research note on Monday, June 15th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $7.50.

SOPHiA GENETICS Stock Up 1.7%

The stock’s 50 day moving average is $5.09 and its 200 day moving average is $4.93. The company has a market capitalization of $510.08 million, a PE ratio of -11.74 and a beta of 0.98. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. The business had revenue of $21.69 million during the quarter, compared to analysts’ expectations of $20.40 million.

Insider Transactions at SOPHiA GENETICS

In related news, insider Philippe Menu sold 5,000 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $5.50, for a total transaction of $27,500.00. Following the sale, the insider owned 240,780 shares of the company’s stock, valued at approximately $1,324,290. This represents a 2.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jurgi Camblong sold 50,069 shares of the firm’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $5.80, for a total value of $290,400.20. Following the completion of the transaction, the chief executive officer owned 3,601,493 shares of the company’s stock, valued at approximately $20,888,659.40. This represents a 1.37% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 263,185 shares of company stock valued at $1,341,645 over the last three months. Company insiders own 4.88% of the company’s stock.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of institutional investors and hedge funds have recently modified their holdings of the company. Perkins Capital Management Inc. purchased a new stake in shares of SOPHiA GENETICS in the fourth quarter worth about $49,000. Squarepoint Ops LLC purchased a new position in SOPHiA GENETICS during the third quarter valued at approximately $49,000. First Dallas Securities Inc. bought a new stake in SOPHiA GENETICS during the 1st quarter worth approximately $50,000. Quadrature Capital Ltd bought a new stake in SOPHiA GENETICS during the 4th quarter worth approximately $54,000. Finally, XTX Topco Ltd bought a new stake in SOPHiA GENETICS during the 4th quarter worth approximately $55,000. 31.59% of the stock is owned by hedge funds and other institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.